Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsenGlobeNewsWire • 09/04/26
Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for InvestorsZacks Investment Research • 08/13/26
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 millionGlobeNewsWire • 08/12/26
Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertideGlobeNewsWire • 08/12/26
Royalty Pharma (RPRX) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 08/05/26
Gear Up for Royalty Pharma (RPRX) Q2 Earnings: Wall Street Estimates for Key MetricsZacks Investment Research • 08/04/26
Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic InitiativesGlobeNewsWire • 08/03/26
Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from NeurimmuneGlobeNewsWire • 07/22/26
Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026GlobeNewsWire • 07/15/26
Are You Looking for a Top Momentum Pick? Why Royalty Pharma (RPRX) is a Great ChoiceZacks Investment Research • 07/10/26
Royalty Pharma PLC (RPRX) Hits Fresh High: Is There Still Room to Run?Zacks Investment Research • 07/10/26
Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/09/26